Randomized, double-blind, placebo-controlled study of the safety and efficacy of different doses and regimens of evinacumab in patients with chronic hypercholesterolaemia despite maximum tolerated lipid-lowering therapy.
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: REGENERON PHARMACEUTICALS, INC.
- Phase: II
- Execution start: 15/05/2018
- End of execution: 30/12/2020
- PI: JUAN DIEGO MEDIAVILLA GARCIA